| Aug 12, 2014
| 1:05 PM
Shares of Dendreon fell as much as 36 percent in morning trading Tuesday after the struggling Seattle biotechnology company warned it might restructure its finances with "no guarantee that any such alternative will provide value for the company's...
| Aug 22, 2011
| 11:50 AM
The price of Seattle Genetics Inc's blood cancer drug Adcetris could top $100,000 for a course of treatment, becoming the latest cancer medicine to come at a high cost.
The U.S. Food and Drug Administration on Friday gave its nod to Adcetris, the first...
| Apr 29, 2010
| 5:15 PM
The Food and Drug Administration approved a new immune-boosting therapy for prostate cancer on Thursday, the first therapeutic vaccine for cancer ever approved by the agency. The approval opens the door to a whole new approach to cancer therapy, adding...
| Apr 29, 2009
An experimental treatment added four months to the lives of men with advanced prostate cancer in a study that tested an entirely new approach to fighting the disease, doctors reported Tuesday.
Dendreon Corp.'s Provenge vaccine trains the immune system to...
| Jun 1, 2010
A new FDA approved treatment developed in Seattle is offering hope for men fighting prostate cancer. Many in the medical world are calling Dendreon's 'Provenge Vaccine-A' cancer treatment a true breakthrough.
The FDA approved Provenge vaccine, a first of...
| Mar 23, 2010
For the first time, an experimental drug has extended the lives of men with advanced prostate cancer who are no longer responding to other treatments and are out of options for fighting the disease, a company-led study found.
The benefit was modest -...
| Sep 21, 2009
| 9:48 PM
Moving out... More and more of Washington's businesses are packing up and heading out of state.
The reason? Some say the state isn't doing what it needs to keep hometown companies happy.
In a non-descript building on the outskirts of Auburn is the...